| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update JS Smolen, RBM Landewé, JWJ Bijlsma, GR Burmester, M Dougados, ... Annals of the rheumatic diseases 79 (6), 685-699, 2020 | 2605 | 2020 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update JS Smolen, RBM Landewé, SA Bergstra, A Kerschbaumer, A Sepriano, ... Annals of the rheumatic diseases 82 (1), 3-18, 2023 | 518 | 2023 |
| Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis … AA den Broeder, MCW Creemers, J Fransen, E de Jong, DJR de Rooij, ... The Journal of rheumatology 34 (4), 689-695, 2007 | 338 | 2007 |
| Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis EEA Arts, C Popa, AA Den Broeder, AG Semb, T Toms, GD Kitas, ... Annals of the rheumatic diseases 74 (4), 668-674, 2015 | 320 | 2015 |
| A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. A Den Broeder, L van de Putte, R Rau, M Schattenkirchner, P Van Riel, ... The Journal of rheumatology 29 (11), 2288-2298, 2002 | 253 | 2002 |
| Long term anti-tumour necrosis factor α monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial … AA Den Broeder, T Saxne, D Heinegård, H Fenner, AMM Miltenburg, ... Annals of the rheumatic diseases 61 (4), 311-318, 2002 | 231 | 2002 |
| A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two … LG Schipper, M Vermeer, HH Kuper, MO Hoekstra, CJ Haagsma, ... Annals of the rheumatic diseases 71 (6), 845-850, 2012 | 198 | 2012 |
| Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non … N van Herwaarden, A van der Maas, MJM Minten, FHJ van den Hoogen, ... bmj 350, 2015 | 187 | 2015 |
| The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients EEA Arts, J Fransen, AA den Broeder, CD Popa, PLCM van Riel Annals of the rheumatic diseases 74 (6), 998-1003, 2015 | 185 | 2015 |
| Subjective complaints as the main reason for biosimilar discontinuation after openlabel transition from reference infliximab to biosimilar infliximab L Tweehuysen, BJF van den Bemt, IL van Ingen, AJL de Jong, ... Arthritis & Rheumatology 70 (1), 60-68, 2018 | 172 | 2018 |
| Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid … SAA van Dartel, J Fransen, W Kievit, M Flendrie, AA den Broeder, ... Annals of the rheumatic diseases 72 (6), 895-900, 2013 | 159 | 2013 |
| Effects of treatment with a fully human anti-tumour necrosis factor α monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFα in patients with … P Barrera, AA Den Broeder, LBA Van de Putte, P Van Riel, ... Annals of the rheumatic diseases 60 (7), 660-669, 2001 | 156 | 2001 |
| Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis M Flendrie, MCW Creemers, PMJ Welsing, AA Den Broeder, P Van Riel Annals of the Rheumatic Diseases 62 (suppl 2), ii30-ii33, 2003 | 154 | 2003 |
| Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms EEA Arts, CD Popa, AA Den Broeder, R Donders, A Sandoo, T Toms, ... Annals of the rheumatic diseases 75 (4), 674-680, 2016 | 149 | 2016 |
| Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register W Kievit, J Fransen, EMM Adang, AA den Broeder, HJ Bernelot Moens, ... Rheumatology 50 (1), 196-203, 2011 | 141 | 2011 |
| Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with antiTNFα AA Den Broeder, MCW Creemers, AM Van Gestel, P Van Riel Rheumatology 41 (6), 638-642, 2002 | 139 | 2002 |
| Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study A van der Maas, E Lie, R Christensen, E Choy, YA de Man, P van Riel, ... Annals of the rheumatic diseases 72 (11), 1800-1805, 2013 | 132 | 2013 |
| Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study A van der Maas, W Kievit, BJF van den Bemt, FHJ van den Hoogen, ... Annals of the rheumatic diseases 71 (11), 1849-1854, 2012 | 129 | 2012 |
| Evidence-based tailored conservative treatment of knee and hip osteoarthritis: between knowing and doing GF Snijders, AA Den Broeder, P Van Riel, V Straten, FHR De Man, ... Scandinavian journal of rheumatology 40 (3), 225-231, 2011 | 126 | 2011 |
| Downtitration and discontinuation strategies of tumor necrosis factor–blocking agents for rheumatoid arthritis in patients with low disease activity N Van Herwaarden, AA den Broeder, W Jacobs, A van der Maas, ... Cochrane database of systematic reviews, 2014 | 124 | 2014 |
